Skip to main content

Table 5 Breakdown of patients, events, total observation time (in years) and death rate according to the 4 risk category proposed model and the MSKCC model.

From: Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model

Events/Patients Proposed model
   0 risk 1 risk 2 risk 3 risk Total
MSKCC model Favorable risk 0/6 1/9 0/0 0/0 1/15
  Intermediate risk 1/9 10/26 13/20 0/0 24/55
  Poor risk 0/0 3/5 9/14 6/6 18/25
  Total 1/15 14/40 22/34 6/6 43/95
Events/Total observation time (in years) 1 Proposed model
   0 risk 1 risk 2 risk 3 risk Total
MSKCC model Favorable risk 0/5.5 1/14.5 0/NA 0/NA 1/20
  Intermediate risk 1/12.7 10/26.3 13/18.1 0/NA 24/57.1
  Poor risk 0/NA 3/5.1 9/11.2 6/2.7 18/19
  Total 1/18.2 14/45.9 22/29.3 6/2.7 43/96.1
Total observation time (in years) 1
(Death rate per year in observation)
Proposed model
   0 risk 1 risk 2 risk 3 risk Total
MSKCC model Favorable risk 5.5 (0) 14.5 (0.07) NA NA 20 (0.05)
  Intermediate risk 12.7 (0.08) 26.3 (0.38) 18.1 (0.72) NA 57.1 (0.42)
  Poor risk NA 5.1 (0.59) 11.2 (0.80) 2.7 (2.22) 19 (0.95)
  Total 18.2 (0.05) 45.9 (0.30) 29.3 (0.75) 2.7 (2.22) 96.1 (0.45)
  1. 1Defined as the time up to last contact or death
  2. 2NA: Not applicable due to non-existing cases in these categories